BlinkLab

The Pharmacology of Human Decision Making Study with Monash University

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological disorders, is pleased to announce a new study to run in partnership with Monash University. The study will evaluate BlinkLab as a medical device able to monitor the therapeutic effects of ketamine on cognitive processes whereby sensory information is converted into decision making. In the future, results from this study can help facilitate cognitive behavioural therapy outcomes in patients with psychiatric conditions such as depression, schizophrenia, epilepsy, and post-traumatic stress disorder (PTSD).


Highlights

  • Study provides a unique opportunity to discover the building blocks of cognition with the potential to transform our understanding of a range of clinical conditions including depression, schizophrenia, epilepsy, PTSD.
  • Potential to demonstrate that drugs targeting glutamatergic neurotransmission can treat some aspects of psychiatric disease symptomology or improve the efficacy of cognitive behavioural therapy.
  • Evaluates ability of BlinkLab tests to be used as a tool to measure pharmacological effects of existing and novel therapeutic agents.

Significance of the Study

Perceptual decision-making is a fundamental cognitive process where sensory information is transformed into meaningful interpretations of the environment, guiding our actions. This field has flourished through the integration of neuroscience and mathematical modelling , providing a robust framework for investigating the neural mechanisms involved. The core idea is that decisions are based on the accumulation of sensory evidence until a decision threshold is reached. These advancements offer a unique opportunity to uncover the fundamental components of cognition and have the potential to revolutionise our understanding of various clinical conditions. By characterising underlying mechanistic abnormalities, refining clinical classifications, and identifying intervention targets, this research holds promise for significant clinical advancements and new therapies for a variety of psychiatric and neurodevelopmental conditions.

The study, conducted by the School of Psychological Sciences at Monash University will investigate the impact of glutamate challenge on perceptual decision making (including behavioural performance, sensorimotor gating) by administering ketamine while participants perform a prepulse inhibition test using BlinkLab application.

The study will be able to demonstrate whether administration of ketamine can disrupt basic sensory encoding mechanisms, which will be detectable in reduced prepulse inhibition.

Study Design

The study will recruit up to 35 healthy adults between 18-55 years old. Each participant will complete 3 testing sessions after ketamine administration. Their participation is expected to take 4-5 weeks per subject.

Terms of the Collaboration Agreement (“Agreement”)

  • Responsibilities: BlinkLab will provide access to its technology, data and shall facilitate the use of its platform during the term of the Agreement.
  • Financial arrangements: None at the date of signing (to be determined via mutual agreement in the future and in a separate agreement).
  • Intellectual Property: Each party will retain all right, title and interest in and to its background intellectual property (copyright, trademarks, designs, know how, patents, plant varieties, confidential information and all other intellectual property as defined in article 2 of the Convention establishing the World Intellectual Property Organization 1967). Any project IP (generated through the study) will be owned by Monash University.
  • Term: Date of signature by the last party to sign (5 August 2024), until completion of the Research Project as communicated by Monash.
  • Termination: Either party may terminate this Agreement by giving between 5 and 20 days written notice (at the terminating party’s election) to the other party if the other party commits a material breach of the Agreement and does not remedy that breach within 10 days after receiving notice requiring them to do so. Monash may terminate this agreement with immediate effect by giving written notice to BlinkLab.
  • Confidentiality: Standard confidentiality terms for an agreement of this nature included.

This announcement has been approved by the Board of Directors.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less

Revolutionising Mental Health Care Through Mobile Solutions

US Autism Diagnostic Study Commences with First Child Tested

US Autism Diagnostic Study Commences with First Child Tested

BlinkLab Limited (BB1:AU) has announced US Autism Diagnostic Study Commences with First Child Tested

Download the PDF here.

Robotic hand and human hand reaching out to touch glowing brain.

ASX AI Stocks: 5 Biggest Companies

Artificial intelligence (AI) continues to evolve and advance rapidly, becoming increasingly integrated in the automation of everyday life and a focal point of growth in the technology sector.

According to a September 2023 report from IDC on worldwide AI spending, Australia, along with Korea and India, is leading the Asia-Pacific region in spending on AI solutions; the three countries are also leading when it comes to AI adoption in the area. Spending in the region, excluding Japan and China, is expected to reach US$28.2 billion by 2027.

Although the AI market is relatively small in Australia, it’s growing. To help investors understand the options available, the Investing News Network used TradingView's stock screener to find the top AI stocks on ASX by market cap. All ASX AI stocks data was current as of April 7, 2025. companies whose businesses are focused mainly on AI were considered.

Keep reading...Show less
Hands holding a glowing AI circuit with digital network icons.

AI Market Update: Q1 2025 in Review

The first quarter of 2025 was dynamic and often volatile for the tech sector. Initial optimism, fueled by investor enthusiasm after a strong 2024, quickly gave way to economic headwinds and market anxieties.

Concerns over monetary policy, global trade tensions and individual company performances led to variations in tech stock valuations, with the Magnificent Seven ultimately experiencing losses by March.

However, Q1 also brought groundbreaking developments in artificial intelligence (AI), intense competition in the semiconductor industry and new developments in AI agents and robotics.

Keep reading...Show less
Man holding magnifying glass.

Tech 5: CoreWeave IPO Falls Short, OpenAI Close to Completing US$40 Billion Funding Round

This week brought a fresh set of challenges to the tech sector, beginning with an announcement from the US Bureau of Industry and Security on Tuesday (March 25) of new export restrictions targeting 80 companies across Asia and the Middle East, impacting some of Big Tech’s key customers.

Consumer confidence weakened, further dampening market sentiment.

This was evidenced by the release of the Conference Board’s Consumer Confidence Index report on Tuesday, and the University of Michigan’s consumer sentiment survey, released on Friday (March 28).

Keep reading...Show less
Hand holding an AI chip.

Global AI Stocks: 9 Biggest Companies in 2025

As the artificial intelligence (AI) market continues to grow, there are many AI stocks for investors to choose from on top exchanges like the NASDAQ, TSX and ASX.

AI technology has made strong inroads into several key industries, including logistics, manufacturing, finance, healthcare, customer service and cybersecurity.

The technology has been around for a long time, but this current wave of buzz comes after the release of OpenAI’s ChatGPT, a generative AI platform. This intelligent chatbot shows how quickly generative AI is advancing, and it has led to many other major tech firms entering the space with their own generative AI offerings or including AI technology into their innovative products.

Keep reading...Show less
RocketBoots

RocketBoots Partners with Global POS Software Vendor to Drive Customer Markets Penetration

Artificial Intelligence software company, RocketBoots Limited (ASX:ROC) (RocketBoots or the Company), is pleased to announce the signing of a partnership agreement with global point-of-sale (POS) vendor, GEBIT Solutions GmbH (Gebit).

Keep reading...Show less
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×